Global Vaccine Market At 10% Growth, Poised For Therapeutic Vaccines
This article was originally published in PharmAsia News
Executive Summary
Robust growth is expected in the global vaccines market driven by new players and products, improved coverage and distribution in both developed and emerging markets, and higher prices for new vaccines, an IMS consultant said during a New York Pharma Forum presentation.
You may also be interested in...
Corporate Responsibility With Teeth: GSK’s Developing Countries Unit
Initiative to build health care infrastructure and create a sales channel for GSK medicines is starting to yield tangible results.
Bringing Urgency And Focus To Takeda: An Interview With Tachi Yamada
In a wide-ranging interview conducted at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business, of the key late-stage assets that will carry the company into the next decade, and of business development priorities in the post-Nycomed era.
Pfizer Sets Its Sights On Therapeutic Cancer Vaccines
The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.